1
|
Hsiao YC, Chueh FS, Ma YS, Lien JC, Hsia TC, Huang WW, Chou YC, Chen PY, Chung JG, Chen HY, Liu KC. Genistein enhances the effects of L-asparaginase on inducing cell apoptosis in human leukemia cancer HL-60 cells. ENVIRONMENTAL TOXICOLOGY 2021; 36:764-772. [PMID: 33347704 DOI: 10.1002/tox.23078] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/07/2020] [Accepted: 11/29/2020] [Indexed: 06/12/2023]
Abstract
Genistein (GEN) has been shown to induce apoptotic cell death in various human cancer cells. L-asparaginase (Asp), a clinical drug for leukemia, has been shown to induce cell apoptosis in leukemia cells. No available information concerning GEN combined with Asp increased the cell apoptosis compared to GEN or Asp treatment alone. The objective of this study is to evaluate the anti-leukemia activity of GEN combined with Asp on human leukemia HL-60 cells in vitro. The cell viability, the distribution of cell cycle, apoptotic cell death, and the level of ΔΨm were examined by flow cytometric assay. The expressions of apoptosis-associated proteins were measured by western blotting. GEN combined with Asp revealed a more significant decrease in total viable cells and induced a higher percentage of G2/M phase arrest, DNA damage, and cell apoptosis than that of GEN or Asp treatment only in HL-60 cells. Furthermore, the combined treatments (GEN and Asp) showed a higher decrease in the level of ΔΨm than that of GEN or Asp treatment only. These results indicated that GEN combined with Asp induced mitochondria dysfunction by disrupting the mitochondrial membrane potential. The results from western blotting demonstrated that the treatment of GEN combined with Asp showed a higher increase in the levels of Bax and Bak (pro-apoptotic proteins) and an active form of caspase-3 and a higher decrease in Bcl-2 (anti-apoptotic protein) than that of GEN or Asp treatment alone. GEN significantly enhances the efficiency of Asp on cytotoxic effects (the induction of apoptosis) in HL-60 cells.
Collapse
Affiliation(s)
- Yin-Chen Hsiao
- Department of Biological Science and Technology, China Medical University, Taichung, Taiwan
| | - Fu-Shin Chueh
- Department of Food Nutrition and Health Biotechnology, Asia University, Taichung, Taiwan
| | - Yi-Shih Ma
- School of Chinese Medicine for Post-Baccalaureate, College of Medicine, I-Shou University, Kaohsiung, Taiwan
- Department of Chinese Medicine, E-Da Cancer Hospital, Kaohsiung, Taiwan
| | - Jin-Cherng Lien
- School of pharmacy, China Medical University, Taichung, Taiwan
| | - Te-Chun Hsia
- Department of Respiratory Therapy, China Medical University, Taichung, Taiwan
- Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan
| | - Wen-Wen Huang
- Department of Biological Science and Technology, China Medical University, Taichung, Taiwan
| | - Yu-Cheng Chou
- Department of Neurosurgery, Neurological Institute, Taichung Veterans General Hospital, Taichung, Taiwan
- Department of Neurological Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan
| | - Po-Yuan Chen
- Department of Biological Science and Technology, China Medical University, Taichung, Taiwan
| | - Jing-Gung Chung
- Department of Biological Science and Technology, China Medical University, Taichung, Taiwan
| | - Hung-Yi Chen
- Department of Pharmacy, China Medical University, Taichung, Taiwan
- Department of Pharmacy, China Medical University Beigang Hospital, Beigang, Yunlin, Taiwan
| | - Kuo-Ching Liu
- Department of Medical Laboratory Science and Biotechnology, China Medical University, Taichung, Taiwan
| |
Collapse
|
2
|
Meghavarnam AK, Salah M, Sreepriya M, Janakiraman S. Growth inhibitory and proapoptotic effects ofl-asparaginase fromFusarium culmorumASP-87 on human leukemia cells (Jurkat). Fundam Clin Pharmacol 2016; 31:292-300. [DOI: 10.1111/fcp.12257] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2016] [Revised: 11/16/2016] [Accepted: 11/22/2016] [Indexed: 11/26/2022]
Affiliation(s)
- Anil K. Meghavarnam
- Department of Microbiology and Biotechnology; Bangalore University; Jnana Bharathi Campus Bangaluru 560056 Karnataka India
| | - Maryam Salah
- Centre of Advanced Study in Marine Biology; Faculty of Marine Sciences; Annamalai University; Parangipettai 608502 Tamil Nadu India
| | - Meenakshisundaram Sreepriya
- Department of Microbiology and Biotechnology; Bangalore University; Jnana Bharathi Campus Bangaluru 560056 Karnataka India
| | - Savitha Janakiraman
- Department of Microbiology and Biotechnology; Bangalore University; Jnana Bharathi Campus Bangaluru 560056 Karnataka India
| |
Collapse
|
3
|
Prakasham RS, Hymavathi M, Subba Rao C, Arepalli SK, Venkateswara Rao J, Kennady PK, Nasaruddin K, Vijayakumar JB, Sarma PN. Evaluation of Antineoplastic Activity of Extracellular Asparaginase Produced by Isolated Bacillus circulans. Appl Biochem Biotechnol 2009; 160:72-80. [DOI: 10.1007/s12010-009-8679-8] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2008] [Accepted: 05/18/2009] [Indexed: 10/20/2022]
|
4
|
Tabandeh MR, Aminlari M. Synthesis, physicochemical and immunological properties of oxidized inulin–l-asparaginase bioconjugate. J Biotechnol 2009; 141:189-95. [DOI: 10.1016/j.jbiotec.2009.03.020] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2008] [Revised: 03/23/2009] [Accepted: 03/30/2009] [Indexed: 11/27/2022]
|
5
|
Narta UK, Kanwar SS, Azmi W. Pharmacological and clinical evaluation of L-asparaginase in the treatment of leukemia. Crit Rev Oncol Hematol 2006; 61:208-21. [PMID: 17011787 DOI: 10.1016/j.critrevonc.2006.07.009] [Citation(s) in RCA: 216] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2006] [Revised: 06/10/2006] [Accepted: 07/06/2006] [Indexed: 11/27/2022] Open
Abstract
L-Asparaginase is an effective antineoplastic agent, used in the acute lymphoblastic leukemia chemotherapy. It has been an integral part of combination chemotherapy protocols of pediatric acute lymphoblastic leukemia for almost 3 decades. The potential of L-asparaginase as a drug of leukemia has been a matter of discussion due to the high rate of allergic reactions exhibited by the patients receiving the medication of this enzyme drug. Frequent need of intramuscular injection has been another disadvantage associated with the native preparation. However, of late these clinical complications seem to have been addressed by modified versions of L-asparaginase. PEG-L-asparaginase proves to be most effective in this regard. It becomes important to discuss the efficacy of L-asparaginase as an antileukemic drug vis-a-vis these disadvantages. In this review, an attempt has been made to critically evaluate the pharmacological and clinical potential of various preparations of L-asparaginase as a drug. Advantages of PEG-L-asparaginase over native preparations and historical developments of therapy with l-asparaginase have also been outlined in the review below.
Collapse
Affiliation(s)
- Umesh K Narta
- Department of Biotechnology, Himachal Pradesh University, Summer Hill, Shimla, India
| | | | | |
Collapse
|
6
|
Ronghe M, Burke GA, Lowis SP, Estlin EJ. Remission induction therapy for childhood acute lymphoblastic leukaemia: clinical and cellular pharmacology of vincristine, corticosteroids, L-asparaginase and anthracyclines. Cancer Treat Rev 2001; 27:327-37. [PMID: 11908926 DOI: 10.1053/ctrv.2001.0243] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Remission induction therapy with vincristine, a corticosteroid, L-asparaginase and an anthracycline has been the mainstay of the initial phase of treatment for childhood acute lymphoblastic leukaemia (ALL) for the past 25 years. The speed and depth of the early response to remission induction therapy has become an important determinant of the intensity of subsequent therapy in many protocols worldwide. Moreover, the detection of significant levels of minimal residual disease at the end of remission induction may have an important bearing on subsequent outcome. Although these clinical observations may reflect, in part, the inherent sensitivity of lymphoblasts to remission induction therapy, the pharmacology of these agents in relation to childhood ALL may also play an important part in early response to therapy. In-vitro studies of human leukaemia cell lines indicate that both the extracellular fluid concentration and duration of exposure to vincristine and anthracyclines are important determinants of cytotoxicity. For L-asparaginase and corticosteroids, the cellular and molecular pharmacological determinants of chemosensitivity have been partially characterized, but further work is needed in this area. The clinical pharmacology of vincristine and L-asparaginase have been well characterized in relation to childhood ALL, and considerable interpatient pharmacokinetic variability exists for these drugs. For corticosteroids and anthracyclines, pharmacology studies are needed in order to fully characterize and understand the factors influencing interpatient pharmacokinetic variability for these agents in relation to childhood ALL. Whereas the relationship between the clinical pharmacology, and potentially important pharmacodynamic effects such as asparagine depletion, has been well characterized for therapy with L-asparaginase, similar studies have yet to be performed for the other drugs that form the mainstay of remission induction therapy for childhood ALL. Therefore, further studies are required to investigate the relative importance of the clinical and cellular pharmacology of vincristine, corticosteroids, L-asparaginase and anthracyclines in the speed and depth of response to remission induction therapy for childhood ALL. Where these have been studied, interindividual differences in the clinical and cellular pharmacology of anticancer agents have been shown to be important determinants of the long-term disease-free survival for children with ALL.
Collapse
Affiliation(s)
- M Ronghe
- Department of Paediatric Oncology, Royal Hospital for Sick Children, St Michael's Hill, Bristol, UK
| | | | | | | |
Collapse
|